Shanton's Innovative Treatment for Refractory Gout
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout.
Shanton Pharma, known for its commitment to advancing biopharmaceutical therapies, recently announced significant topline data from a Phase 2b study involving refractory gout patients. This innovative drug, SAP-001, employs a unique First-in-Class Mechanism of Action aimed at targeting specific kidney transporters, marking a new era in gout management.
Dr. Bing Li, Shanton's CEO, expressed enthusiasm about the study results. He noted, "The Phase 2b clinical study yielded promising outcomes, particularly for refractory gout patients who have limited treatment options. By the third month, nearly all participants receiving 30 and 60 mg dosages of SAP-001 alongside their usual therapies had serum uric acid levels fall below the target of 6 mg/dL. In stark contrast, only about 10% of those on conventional treatments achieved this level. The durability of treatment effects persisted through the six-month duration, with over half of patients on the 60 mg dose achieving even lower uric acid levels, at below 3 mg/dL. Additionally, the study highlighted an excellent safety profile, further supporting the drug's potential."
Shanton's previous trials have demonstrated promising efficacy, surpassing other Urate Lowering Therapies in both earlier Phase 1 and 2a studies involving regular gout patients. The remarkable results in this more challenging group of refractory patients emphasize the importance of novel treatment strategies in managing severe forms of gout. Dr. Wenfeng Miao, Shanton’s Chief Medical Officer, elaborated, "This successful clinical study with an oral drug for refractory gout patients is groundbreaking. Historically, these patients required intravenous therapies. The impressive efficacy and safety characteristics observed in SAP-001 across multiple dosage groups further confirm our belief in its potential to transform gout treatment. A new mechanism of action targeting specific kidney transporters could revolutionize care, especially for patients historically inadequately addressed by current therapies. Our aim is to move into pivotal studies soon and provide a significant impact on the lives of our patients."
Understanding Gout
Gout is the most prevalent inflammatory arthritis and ranks as the second most common metabolic disorder. Characterized by excessive uric acid levels in the blood, it affects over 12 million adults in the United States. When urate crystals settle in the joints, they can trigger painful attacks known as flares, debilitating those affected. Chronic gout can result in severe joint damage and long-term complications.
Currently, only 29% of diagnosed gout patients in the US are being treated with urate lowering therapies. Unfortunately, of these, only half respond adequately or can endure the existing treatment option's side effects. Research indicates that a significant portion of patients on standard treatments like allopurinol or febuxostat may be physiologically unresponsive to these therapies.
Details of Shanton's Phase 2b Study
In this pivotal Phase 2b study, Shanton enrolled 87 patients across 21 sites for a six-month, randomized, double-blinded trial emphasizing the efficacy and safety of SAP-001 in refractory gout patients with or without tophi. The primary aim focused on evaluating the compound's effectiveness in reducing serum urate levels, while secondary objectives comprised safety evaluations and tracking gout flare incidences.
About Shanton Pharma
Founded in 2016, Shanton Pharma is a privately held biotech company focused on addressing unmet needs associated with hyperuricemia and gout treatment. Headquartered in Singapore, the company operates research and development activities across multiple regions including the US and China. SAP-001 stands out as Shanton's flagship investigational compound aimed at providing a once-daily oral urate-lowering therapy. The promising results from prior clinical studies place it among the best-in-class drugs for treating hyperuricemia, particularly in patients unresponsive to standard therapies.
Frequently Asked Questions
What is SAP-001?
SAP-001 is an investigational drug developed by Shanton Pharma targeting refractory gout through a unique mechanism of action.
What were the results of the Phase 2b study?
The Phase 2b study showed promising outcomes, with nearly all patients on SAP-001 achieving serum uric acid levels below 6 mg/dL by month three.
What safety profile did SAP-001 demonstrate?
The study indicated an excellent safety profile, reinforcing confidence in its potential for broad clinical use.
Why is SAP-001 significant for refractory gout patients?
This treatment option is crucial as it provides a new oral therapy for patients who often rely on intravenous treatments.
What are Shanton Pharma's future plans for this treatment?
Shanton aims to progress into pivotal studies later this year, seeking to bring-effective gout therapies to market and improve patient outcomes.
